EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells

Filipa Amaro, Márcia Carvalho iD, Maria de Lourdes Bastos, Paula Guedes de Pinho iD, Joana Pinto iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25126328 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Filipa Amaro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Associate Laboratory i4HB-Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Kidney Neoplasms, Protein Kinase Inhibitors, Sunitinib. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, Research Unit on Applied Molecular Biosciences-UCIBIO, Associate Laboratory Institute for Health and Bioeconomy-i4HB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of resistance to tyrosine kinase inhibitors (TKIs) is a major cause of treatment failure in metastatic renal cell carcinoma (mRCC). A deeper understanding of the metabolic mechanisms associated with TKI resistance is critical for refining therapeutic strategies. In this study, we established resistance to sunitinib and pazopanib by exposing a parental Caki-1 cell line to increasing concentrations of sunitinib and pazopanib. The intracellular and extracellular metabolome of sunitinib- and pazopanib-resistant mRCC cells were investigated using a nuclear magnetic resonance (NMR)-based metabolomics approach. Data analysis included multivariate and univariate methods, as well as pathway and network analyses. Distinct metabolic signatures in sunitinib- and pazopanib-resistant RCC cells were found for the first time in this study. A common metabolic reprogramming pattern was observed in amino acid, glycerophospholipid, and nicotinate and nicotinamide metabolism. Sunitinib-resistant cells exhibited marked alterations in metabolites involved in antioxidant defence mechanisms, while pazopanib-resistant cells showed alterations in metabolites associated with energy pathways. Sunitinib-resistant RCC cells demonstrated an increased ability to proliferate, whereas pazopanib-resistant cells appeared to restructure their energy metabolism and undergo alterations in pathways associated with cell death. These findings provide potential targets for novel therapeutic strategies to overcome TKI resistance in mRCC through metabolic regulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmKidney NeoplasmsProtein Kinase InhibitorsSunitinibSulfonamidesMetabolomicsIndazolesCarcinoma, Renal CellPyrimidinesHumansCell Line, TumorMetabolomeCell ProliferationTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

drug resistancemetabolic reprogrammingmetabolomicsrenal cell carcinomatyrosine kinase inhibitors

Substanzen

pazopanibProtein Kinase InhibitorsSunitinibSulfonamidesIndazolesPyrimidinesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Associate Laboratory i4HB-Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal.
  • UCIBIO-Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
  • RISE-UFP, Health Research Network, Faculty of Health Sciences, University Fernando Pessoa, 4200-150 Porto, Portugal.

ORCID-Profile: Márcia Carvalho, Paula Guedes de Pinho, Joana Pinto

Förderung

  • Fundação para a Ciência e Tecnologia
  • Research Unit on Applied Molecular Biosciences-UCIBIO
  • Associate Laboratory Institute for Health and Bioeconomy-i4HB
  • FCT
  • Scientific Employment Stimulus

Zitieren

APA

Amaro, F., Carvalho, M., Bastos, M. L., Guedes de Pinho, P., & Pinto, J. (2024). Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126328

Vancouver

Amaro F, Carvalho M, Bastos ML, Guedes de Pinho P, Pinto J. Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126328

BibTeX
@article{Amaro2024,
  author = {Amaro, Filipa and Carvalho, Márcia and Bastos, Maria de Lourdes and Guedes de Pinho, Paula and Pinto, Joana},
  title = {Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25126328}
}
Kostenlos starten →